Mr. Miguel Martin reports

AURORA CANNABIS AND VECTURA FERTIN PHARMA, INC. ANNOUNCE LAUNCH OF NOVEL LUO CBD LOZENGE

Aurora Cannabis Inc. has launched the newly developed Luo CBD (cannabidiol) lozenge.

The high-quality CBD lozenge was developed by Vectura Fertin Pharma and adheres to stringent safety, quality and regulatory standards to address unmet medical and health needs. It is the first of Vectura Fertin Pharma's medical cannabis products to launch in Canada. The CBD lozenge is being manufactured, packaged and labelled by Cogent, a Vectura Fertin Pharma subsidiary, for sale and will be distributed by Aurora through its leading direct-to-patient e-commerce platform. The CBD lozenge, which has a novel dissolvable format and is easy to dose, is now available for patients on Aurora's Canadian medical cannabis patient platform as authorized by health care professionals.

Miguel Martin, chief executive officer for Aurora, said: "As the leading provider of medical cannabis in Canada, the launch of the newly developed Luo CBD lozenge on our platform is a significant and exciting milestone at the beginning of our strategic collaboration with Vectura Fertin Pharma. We are committed to bringing innovative solutions to patients and this launch reinforces our position at the forefront of Canada's medical cannabis industry."

Michael Kunst, chief executive officer for Vectura Fertin Pharma, said: "The launch of our newly developed Luo CBD lozenge on Aurora's medical cannabis patient platform closely follows the announcement of our joint commercial collaboration in August this year and is testament to our pioneering approach to science-backed innovation to address unmet medical and health needs. Aurora has the largest patient platform in Canada, and the launch will enable us to make a meaningful impact to patients and to validate our product's proposition through real-world patient data."

Through Aurora's leading patient platform, Cogent will gain access to patient feedback on the CBD lozenge, which will be used to validate the product proposition and to build real-world patient data to inform future products. The two companies will explore opportunities regarding the potential commercialization of other Vectura Fertin Pharma medical cannabis products in Canada.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alta., Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched.

Aurora's common shares trade on the Nasdaq Stock Market and the Toronto Stock Exchange under the symbol ACB.

We seek Safe Harbor.